Prasugrel
Back to searchMolecule Structure
Scientific Name
Prasugrel
Description of the Drug
Prasugrel is a P2Y12 platelet inhibitor used to reduce risk of thrombotic cardiovascular events in unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and in patients with STEMI when managed with either primary or delayed PCI.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06209
http://www.drugbank.ca/drugs/DB06209
Brand Name(s)
Efient
Company Owner(s)
Chartwell Rx Sciences Llc, Accord Healthcare Inc, Aurobindo Pharma Ltd, Dr Reddys Laboratories Ltd, Mylan Pharmaceuticals Inc, Amneal Pharmaceuticals Of New York Llc, Hec Pharm Usa Inc, Panacea Biotec Pharma Ltd, Cosette Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Purinergic receptor P2Y12 | SINGLE PROTEIN | ANTAGONIST | CHEMBL2001 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL245032 | ||
| PharmGKB | PA154410481 | ||
| Human Metabolome Database | HMDB0015625 | ||
| DrugBank | DB06209 | ||
| PubChem: Thomson Pharma | 14755496 | ||
| PubChem | 6918456 | ||
| Mcule | MCULE-1302242257 | ||
| Nikkaji | J1.292.848C | ||
| DrugCentral | 4113 | ||
| Brenda | 72089 | 71273 | |
| ChemicalBook | CB01463424 | ||
| Guide to Pharmacology | 7562 | ||
| rxnorm | PRASUGREL HYDROCHLORIDE | EFFIENT | PRASUGREL |
| PubChem: Drugs of the Future | 12015290 | ||
| ChEBI | 87723 |
